EBSEmergent BioSolutions Inc.
Is the business good?
Margins widening. That is the only one of 4 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Operating margin has widened over the past few years, the business is getting more profitable per dollar of sales.
Where this answer is blind. The F-score rewards improvement, so an already-elite company can score mid-pack.
How good a business is EBS?
Emergent BioSolutions Inc. earns −6.7% on the capital it employs against a 9.0% cost of capital, so growth costs more than it returns.
Return on invested capital · cost of capital 9.0% · 16 points below what the capital costs: growth destroys value
- Operating margin
- −8.6%
Operating margin · Drug Manufacturers - Specialty & Generic median 9.5% · 12 months to Q2 2026
- Share count, year on year
- −4.8%
Share count, year on year · bought back, each share owns more of the company
- R&D as % of revenue
- 5.9%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2020 | 28% |
| FY2021 | 19% |
| FY2022 | −15% |
| FY2023 | −69% |
| FY2024 | −10% |
| FY2025 | 13% |
Details›
- Gross margin12 months to Q2 2026
- 56%
- Operating margin12 months to Q2 2026
- −8.6%
- Net margin12 months to Q2 2026
- −23%
- Free cash flow margin
- 11%
- R&D as % of revenue
- 5.9%
- Revenue, trailing twelve months
- $770M
- Free cash flow, trailing twelve months
- $86M
- Net income, trailing twelve months
- −$177M
- Return on invested capitaloperating profit after tax ÷ debt + equity − cash
- −6.7%
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
Customers and suppliers
Who buys from EBS and who it buys from, as the companies report it.
- U.S. government46%
Share of revenue · FY2025 10-K
None disclosed.
A company has to disclose every customer behind 10% or more of its revenue. Each share comes from the latest annual report of the company that states it and shows on both companies’ pages; EBS’s own figures are from its FY2025 10-K. Smaller customers and suppliers go unreported.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 39 by RyuScore